Inhibrx Biosciences, Inc. (INBX) intrinsic value & 10-year financials
Inhibrx Biosciences, Inc. (INBX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue shrank 15.0% a year to $1.3M, with an average return on invested capital of 1218.9%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $89.83
- Market cap
- $1.4B
- Revenue (FY2025)
- $1.3M
- Revenue growth (4-yr CAGR)
- -15.0%
- ROIC (10-yr avg)
- 1218.9%
- Free cash flow (FY2025)
- -$129.8M
INBX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.3M | -$140.1M | -$9.04 | -$129.8M | -10386.5% | 1120.5% |
| FY2024 | $200.0K | $1.7B | $112.62 | -$197.0M | -165724.0% | 1704.0% |
| FY2023 | $1.8M | -$241.4M | -$20.48 | -$197.9M | -12178.9% | 832.2% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Inhibrx Biosciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Inhibrx Biosciences, Inc. returns on capital have been average, hovering around 12.2% ROIC over the decade.
Inhibrx Biosciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Inhibrx Biosciences, Inc. is modeled at -15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-2092.88 per share.